Friday, 16 October 2026European Markets

BORREGAARD Stock Rises By 16% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of BORREGAARD (Oslo Børs All-share Index_GI: BRG.OL) jumped by a staggering 16.09% in 5 sessions from $156.6 to $181.80 at 13:36 EST on Monday, after two successive sessions in a row of gains. Oslo Børs All-share Index_GI is falling 0.89% to $1,365.78, after consecutive sessions in a row of losses.

About BORREGAARD

Borregaard ASA develops, produces, and markets specialized biomaterials, biochemicals, and biofuels in Norway, rest of Europe, the United States, Asia, and internationally. It operates through three segments: BioSolutions, BioMaterials, and Fine Chemicals. The BioSolutions segment provides biopolymers for a range of applications, such as agrochemicals, batteries, industrial binders, and construction; and biovanillin for flavor and fragrance companies, as well as for food and beverage industry. The BioMaterials segment offers specialty cellulose for use as a raw material in the production of cellulose ethers, cellulose acetate, and other specialty products; and cellulose fibrils for industrial applications. The Fine Chemicals segment provides fine chemical intermediates for contrast agents; and bioethanol. Borregaard ASA was incorporated in 2012 and is headquartered in Sarpsborg, Norway.

Earnings Per Share

As for profitability, BORREGAARD has a trailing twelve months EPS of $4.81.

PE Ratio

BORREGAARD has a trailing twelve months price to earnings ratio of 37.76. Meaning, the purchaser of the share is investing $37.76 for every dollar of annual earnings.

Volume

Today's last reported volume for BORREGAARD is 108267 which is 33.07% above its average volume of 81358.

More news about BORREGAARD (BRG.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com